ESTRO 2024 - Abstract Book

S2077

Clinical - Sarcoma, skin cancer, melanoma

ESTRO 2024

thereafter. Clinical outcome and therapy related acute and late toxicities have been recorded in course of the follow- up (FU). The data was analyzed, comparing the posttreatment scores to each patient’s baseline. In order to assess the impact of the clinical outcome and toxicities on HRQoL, the scores were correlated to clinical outcomes.

Results:

Median FU was 51 months (range, 1-94). Overall survival rates observed were 100%, 93.1% and 85.1% after 1, 3 and 6 years, respectively. Four (5.2%) patients died of tumor-related causes (all chordoma) and three (3.9%) of unrelated causes. Local failure free survival was achieved in 95.6%, 85.5% and 80.3% after 1,3 and 6 years, respectively. Local relapse occurred in and outside the target volume in 10 and 2 patients, respectively. There were no marginal local failures. Distant failure occurred in two (2.6%) chordoma patients. There were no >G3 acute toxicities. One G3 brain radiation necrosis and one G4 optic nerve disorder were documented during FU. HRQoL deteriorated at the completion of PT and returned to baseline values one year thereafter. Gross total resection was correlated to better HRQoL at all time points (p-value 1 year after PT = 0.034). Disease progression was correlated with overall worse HRQoL and higher neurological symptoms already before PT, and higher symptom burden one year thereafter (p value 1 year after PT = 0.038). Males had better HRQoL before and one year after PT than females (p-value 1 year after PT = 0.008). At the end of PT, besides of neurological symptoms, which were significantly lower in males, there was no further correlation of global HRQoL or symptom burden with gender.

Conclusion:

PT achieves an excellent local and distant control in patients with skull base chordoma and ChoSa, with a low probability of radiation-induced adverse events. The HRQoL in these patients decreases at treatment completion, returns to the baseline from one year thereafter. Failure status, gender and resection status are correlated to suboptimal HRQoL.

Keywords: HRQoL, skull base chordoma, proton therapy

249

Digital Poster

Hypofractionated radiotherapy in soft tissue sarcoma (STS): pathological response and acute toxicity

Laura Guzmán-Gómez, Marta Pérez Cobos, María Sánchez Pérez, Magnolia Rincón Pérez, Ignacio Azinovic

Fundacion Jimenez Diaz University Hospital, Radiation Oncology, Madrid, Spain

Purpose/Objective:

Preoperative radiotherapy (RT) combined with surgery constitute the mainstay of therapy for localized soft tissue sarcoma (STS). Growing evidence suggests that shortening preoperative RT courses by hypofractionation, neither increase toxicity rates, nor impairs oncological outcomes compared to normofractionated RT. We report our